Navigation Links
Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
Date:10/30/2007

cense revenues for the third quarter of 2007 were $1.2 million, compared to $7.3 million in the prior year period. In the third quarter of 2006, royalty and license revenues were high due to $5.0 million of revenue associated with the first payment arising from the successful settlement of Gen-Probe's patent infringement claims against Bayer HealthCare (now Siemens Medical Solutions Diagnostics). Gen-Probe also earned $1.0 million of license revenue in the prior year period under a 2004 agreement with Tosoh Corporation. For the first nine months of 2007, royalty and license revenues were $14.4 million, compared to $9.2 million in the prior year period. This 57% increase resulted primarily from $10.3 million of royalty revenue that was recorded in the first quarter of 2007 associated with the second payment arising from the Bayer patent litigation.

Gross margin on product sales in the third quarter of 2007 was 67.3%, compared to 70.9% in the prior year period. This decrease resulted primarily from an unfavorable product sales mix, namely increased sales of low-margin instrumentation to clinical diagnostics and blood screening customers. For the first nine months of 2007, gross margin on product sales was 67.3%, compared to 68.2% in the prior year period.

Research and development (R&D) expenses in the third quarter of 2007 were $27.6 million, compared to $24.2 million in the prior year period, an increase of 14%. This increase, which was expected, resulted primarily from the purchase of human papillomavirus (HPV) oligonucleotides from Roche. For the first nine months of 2007, R&D expenses were $72.8 million, compared to $63.8 million in the prior year period, an increase of 14%.

Marketing and sales expenses in the third quarter of 2007 were $9.7 million, compared to $9.5 million in the prior year period, an increase of 2%. For the first nine months of 2007, marketing and sales expenses were $28.6 million, compared to $27.5 million in the prior year p
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... how the receptors responsible for contractions in the bladder, ... published today in The FASEB Journal , has ... cycle of all cells in the body. The team ... and its control are weakened in ageing bladders, demonstrating ... ageing. , While currently much is known ...
(Date:8/22/2014)... August 22, 2014 Ophthalmic drug ... interesting and challenging endeavors as the anatomy, physiology ... properties to the foreign substances. Ocular drug delivery ... self medication and minimal use of needles; also ... drugs and provides specific targeting within the ocular ...
(Date:8/22/2014)... The AMA is pleased to share ... Alaska that Alaska Governor Sean Parnell has signed House ... public use of Unmanned Aircraft Systems and the continuation ... 255states that it is, “An Act relating to unmanned ... unmanned aircraft system.” It defines State of Alaska laws ...
(Date:8/21/2014)... LYNBROOK, N.Y. , Aug. 21, 2014 /PRNewswire/ ... a biopharmaceutical company developing first in class collagenase-based ... histolyticum or CCH) in the U.S. and XIAPEX ... statistically significant results from a randomized, double-blind Phase ... of cellulite, or edematous fibrosclerotic panniculopathy. The results ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... , , NEW YORK, Sept. ... with Dave Champagne, Vice President and General Manager of Informatics ... Chief Engineer at HUNT Research Center and Biobank, about data ... and challenges at life sciences companies. , ...
... , , BALTIMORE, Sept. 9 ... a company engaged in the development of advanced preclinical platforms and ... present at Rodman & Renshaw,s Eleventh Annual Healthcare Conference taking place ... The company,s Chairman of the Board, Dr. David Sidransky, will present ...
... 9 Oramed Pharmaceticals,Inc. (OTCBB: ORMP.OB), a developer of ... approval from the Institutional Review Board (IRB),to commence human ... was,granted after successful pre-clinical results were reported. The trials ... Center in,Jerusalem. , Currently, all ...
Cached Biology Technology:Don't Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 2Champions Biotechnology to Present at Rodman & Renshaw's Eleventh Annual Healthcare Conference 3Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog 2Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog 3
(Date:8/22/2014)... Access to Research Careers) Program has announced the travel ... Practical Exercises Workshop which will be held on the ... 2014. These awards are meant to help support ... groups in the the FASEB Grant Writing Seminar & ... awards totaling $20,350. , The FASEB MARC Program is ...
(Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
(Date:8/21/2014)... in smog-producing toxins in past decade, GTA still ... shows that while the Greater Toronto Area (GTA) ... contribute to smog, the city continues to violate ... which can cause or aggravate health problems such ... by a set of complex photochemical reactions involving ...
Breaking Biology News(10 mins):Despite a significant reduction in smog-producing toxins, the Greater Toronto Area still violates Canada's standards for ozone air pollution 2
... reconstructions of atmospheric CO2 concentrations and sea level over ... National Oceanography Centre, Southampton have found that greenhouse gas ... million) were systematically associated with sea levels at least ... determined the ,natural equilibrium, sea level for CO2 concentrations ...
... learn that plants grow toward the light. This seems straightforward, ... to grow and move in response to their environment are ... most fundamental processes in plant biologyplant movement in response to ... American Journal of Botany . Plant movements, known ...
... have cast doubt on the widely held perception that ... Blooms, or proliferations, of jellyfish can show a substantial, ... fishermen, stinging waters for tourists, even choked cooling intake ... have created a perception that the world,s oceans are ...
Cached Biology News:New study documents the natural relationship between CO2 concentrations and sea level 2Scientists join forces to bring plant movement to light 2Scientists join forces to bring plant movement to light 3Scientists join forces to bring plant movement to light 4Jellyfish experts show increased blooms are a consequence of periodic global fluctuations 2
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
...
Request Info...
Biology Products: